


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CHANGE OF CORRESPONDENCE ADDRESS

Application

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	10/417,552
Filing Date	December 8, 2004
First Named Inventor	Jean-Pol CASSART
Art Unit	
Examiner Name	
Attorney Docket Number	B45310

Please change the Correspondence Address for the above-identified application to:



The address associated with
Customer Number:

23347

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	ZIP	
Country			
Telephone	Email		

This form cannot be used to change the data associated with a Customer Number. To change the data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124).

I am the:

- Applicant/Inventor
- Assignee of record of the entire interest.
- Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).
- Attorney or Agent of record. Registration Number 37,092
- Registered practitioner named in the application transmittal letter in an application without an executed oath or declaration. See 37 CFR 1.33(a)(1). Registration Number _____

Signature

Typed or Printed Virginia G. CampenDate 13 Sept. 05Telephone (919) 483-1012

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

*Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2



PTO/SB/81 (06-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	PCT/EP2003/006095
	Filing Date	6 June 2003
	First Named Inventor	Jean-Pol CASSART
	Title	IMMUNOGENIC COMPOSITIONS COMPRISING A XENOGENIC PROSTATE PROTEIN PS01S
	Art Unit	
	Examiner Name	
Attorney Docket Number	B45310	

I hereby appoint:

Practitioners associated with the Customer Numbers. 20462

Or

Practitioner(s) named below:

Name	Registration Number

As my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

The address associated with the above-mentioned Customer Number:

Or

The address associated with Customer Number 20462

Or

Firm or Individual Name:

Address:

Address:

City:

Country:

Telephone:

State:

Zip:

Fax:

I am the:

Applicant/Inventor:

Assignee or record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature: Date:
Name: Marcus Jonathan William DALTON Telephone: +44 20 7047 4070 DEC 2004

Title and Company: Attorney and Authorised Official, Glaxo Group Limited

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required.
Submit multiple forms if more than one signature is required, see below*.

*Total of: forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office: US DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**STATEMENT UNDER 37 CFR 3.73(b)****Applicant/Patent Owner: Glaxo Group Limited****International Application No./Patent No.: PCT/EP2003/006095 Filed/Issue Date: 6 June 2003****Entitled: IMMUNOGENIC COMPOSITIONS COMPRISING A XENOGENIC PROSTATE PROTEIN P501S****Glaxo Group Limited, a corporation, states that it is:**

1. the assignee of the entire right, title, and interest; or
 2. an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is 50% in the patent application/patent identified above by virtue of either;

- A. An assignment from the inventor(s) of the patent application/patent identified above: The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which copy thereof is attached.

OR

- B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
 The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
 The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
 The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO.
 See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

10 DEC 2004

Date

Marcus Jonathan William DALTON
 Printed or Typed Name

+44 20 8047 4401
 Telephone Number

Attorney and Authorised Official on behalf of Glaxo Group Limited
 Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**STATEMENT UNDER 37 CFR 3.73(b)****Applicant/Patent Owner:** GlaxoSmithKline Biologicals s.a.**International Application No./Patent No.:** PCT/EP2003/006095 **Filed/Issue Date:** 6 June 2003
Entitled: IMMUNOGENIC COMPOSITIONS COMPRISING A XENOGENIC PROSTATE PROTEIN P501S**GlaxoSmithKline Biologicals s.a. a corporation, states that it is:**

- the assignee of the entire right, title, and interest; or
- an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is 50% in the patent application/patent identified above by virtue of either;

- A. [] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which copy thereof is attached.

OR

- B. [] A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

[] Additional documents in the chain of title are listed on a supplemental sheet.

- [X] Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO.
See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

10 . 12 . 04

Date

Marcus Jonathan William DALTON

Printed or Typed Name

+44 20 8047 4401

Telephone Number

Attorney and Authorised Official on behalf of GlaxoSmithKline Biologicals s.a.

Title

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is essential to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



GlaxoSmithKline

POWER OF ATTORNEY

**GlaxoSmithKline
Biologics s.a.**
Rue de l'Institut, 89
B-1330 Rixensart
Belgium

Tel. +32 (0) 2 656 81 11
Fax. +32 (0) 2 656 80 00
www.gsk.com

BY THIS POWER OF ATTORNEY given this 12th day of June 2002, GLAXOSMITHKLINE BIOLOGICALS S.A. (formerly "SMITHKLINE BEECHAM BIOLOGICALS S.A."), a Company duly incorporated in Belgium under registration number 65945 and having its registered office at 89 rue de l'Institut, B-1330 Rixensart, Belgium, appoints M.J.W. Dalton (hereinafter called "the Attorney") to be the true and lawful Agent and Attorney of the Company on behalf of and in the name of the Company or otherwise to do, perform, exercise and execute or concur with any other person or persons in doing, performing, exercising and executing in any country or countries or jurisdiction in any part of the world all or any of the following powers, act, deeds and things, that is to say:

1. To make application or cause application to be made for the grant to the Company and the proper registration in the name of the Company of any letters patent, registered designs or know-how whatever and to take all steps necessary for the same to be prosecuted and maintained.
2. As the act and deed of the Company to sign, seal and deliver and execute all or any assignments or assurances to the Company of any letters patent, registered designs, know-how or any application therefor for the purpose of fully and effectually vesting and transferring the same into the name of the Company insofar as such documents can be executed without the Company's seal being affixed thereto.
3. As the act and deed for the Company to sign, seal, deliver and execute all or any assignments, assurances, licenses and sub-licenses from the Company of or under any letters patent, registered design, know-how or an application therefor for the purpose of fully and effectually vesting, transferring or granting the same into the name of any person or company (whether in the United Kingdom or elsewhere) insofar as such documents can be executed without the Company's Seal being affixed thereto.
4. To sign and execute all documents relating to applications for letters patent, registered designs, know-how or the renewal thereof or to assignments or assurances of the same or applications therefor.
5. To act in regard to all official communications which may now or hereafter be addressed to the Company or to the Attorney relating to applications for letters patent, registered designs, know-how or the renewal thereof in such manner that the Attorney may be recognized as the authorized Agent of the Company in all proceedings incidental thereto.
6. For, or in connection with any letters patent, registered designs, know-how or application therefor to sign, seal, deliver and execute any Power of Attorney or other deed or document:


- a) authorizing any firm or patent agents in the United Kingdom of Great Britain and Northern Ireland to act on behalf of the Company;
 - b) authorizing any person, persons, firm or company practising as patent agents or otherwise entitled to act as agents for all matters relating to letters patent, registered designs or know-how outside the United Kingdom of Great Britain and Northern Ireland to act on behalf of the Company, with powers of substitution.
7. To initiate or cause to be initiated or to appear as defendant, complainee, interpleader or enjoined third party in any Patent Office or Registry or Court or other agency or government department or otherwise responsible for the registration or protection of letters patent, registered designs or know-how in respect of any proceedings or application whatsoever relating to such proprietary rights whether in the name or the Company of not and to cause such proceedings or applications to be maintained or withdrawn.

AND THE COMPANY HEREBY RATIFIES AND CONFIRMS and agrees to ratify and confirm all and whatsoever the Attorney or any person, persons, firm or company appointed by him shall lawfully do or have done or case to be done by virtue to the authority herein contained, including in such ratification and confirmation all and whatsoever the hereby appointed Attorney may already have done in purported exercise of the authorities presently vested in him.


AND THE COMPANY HEREBY DECLARES that this Power of Attorney is in substitution for and shall revoke all previous Powers of Attorney granted by the Company to the Attorney to do any of the acts and things hereby authorized to be done and remaining unrevoked PROVIDED that nothing herein contained shall affect the validity of any act or thing done by the Attorney by virtue thereof before the execution of this Power.

IN WITNESS WHEREOF the Company has caused its Common Seal to be hereunto affixed the day and year first before written.


GLAXOSMITHKLINE BIOLOGICALS S.A.



Jean-Luc Bocken
Director



Jean-Pierre Suin
Director



ASSIGNMENT

WHEREAS I/We, Jean-Pol CASSART, Catherine Marie Ghislaine GERARD and Remi M PALMANTIER of Rixensart, Belgium have made an invention entitled:

Immunogenic Compositions Comprising a Xenogenic Prostate Protein P501S

for which on _____ I/we executed an application for Letters Patent of the United States of America;

NOW, THEREFORE, in return for valuable consideration paid to me/us by GlaxoSmithKline Biologicals s.a. of rue de l'Institut 89, B-1330 Rixensart, Belgium (hereinafter "ASSIGNEE"), the receipt of which is hereby acknowledged and intending to be legally bound, I/we do hereby assign unto the said ASSIGNEE, its successors and assigns, the entire right, title and interest in and to the said invention, said executed application, any division, continuation and continuation-in-part of said application and reissue applications, and all Letters Patents of the United States of America to be obtained therefor;

I/we hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment and sale;

In addition I/we agree to provide ASSIGNEE upon its request with all pertinent facts and documents relating to said invention, and said Letters Patent as may be known and accessible to me/us, and to testify as to the same in any interference or litigation related thereto, and to execute further instruments (including divisional, continuation, continuation-in-part or reissue applications, affidavits or other instruments) required to apply for, obtain, maintain and enforce said application and said Letters Patent which may be necessary; this agreement to be binding upon my/our heirs, executors and administrators.

Inventor 1
Jean-Pol CASSART

Date: 06/12/04

Inventor 2
Catherine Marie Ghislaine GERARD

Date: 07/12/04

Inventor 4
Remi M PALMANTIER

Date: 7/17/2004

No logy

88860

John Venn & Sons

Scrivener Notaries
Translators


William B Kennair LL.B. • Jessica M Reeve M.A. • Jonathan P Courts M.A., M.I.L
Associate: Agnes Corless
Consultant: Bridget M Ellison S.A.

95 Aldwych London WC2B 4JF
United Kingdom
Telephone: 020 7395 4300
Fax: 020 7395 4310
e-mail: notary@johnvenn.co.uk
<http://www.johnvenn.co.uk>

I, JESSICA MARGARET REEVE, a duly admitted Notary Public, having jurisdiction throughout England and Wales and practising in London, England, hereby certify:

1. THAT the annexed Power of Attorney was sealed with the Common Seal of **GLAXO GROUP LIMITED**;
2. THAT the affixing of the said Seal was witnessed by LORRAINE ANNE DAY, one of the Directors of EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED, Corporate Director of GLAXO GROUP LIMITED and RICHARD JAMES STEPHENS, Assistant Secretary of the said GLAXO GROUP LIMITED;
3. THAT the said GLAXO GROUP LIMITED is duly incorporated and existing under English Law, having its Registered Office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England;
4. THAT the said Seal was affixed in the manner prescribed by the current, duly adopted Articles of Association of the said Company;
5. THAT the said signatures were subscribed by authority of the Directors of the said Company;
6. AND THAT the said Power of Attorney, being so sealed and signed, is duly executed by and binding on the said Company.

IN WITNESS whereof I have issued this Certificate under my signature and Seal of Office at London, aforesaid, the fourth day of March Two thousand and five.




Power of Attorney

BY THIS POWER OF ATTORNEY given this 22nd day of FEBRUARY two thousand and five GLAXO GROUP LIMITED, a company incorporated in England and Wales (Registration No. 305979) and having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (hereinafter called "the Company"). HEREBY appoints all and any of its Directors, Secretary and Assistant Secretary for the time being, and DAVID ROBERTS, PETER JOHN GIDDINGS, ARTHUR WILLIAM RUSSELL TYRELL, MARCUS J. W. DALTON, PETER I. DOLTON, WENDY ANNE FILLER, MICHAEL JOHN STOTT, HUGH BAINFORDE DAWSON, HELEN QUILLIN, CHARLES KINZIG, STEPHEN VENETIANER, THEODORE R. FURMAN, MARY E. MCCARTHY, EDWARD R. GIMMI, CHARLES E. DADSWELL, ROBERT H. BRINK and FRANK P. GRASSLER jointly and severally to be its true and lawful agents and attorneys (hereinafter called "the Attorneys") on behalf and in the name of the Company or otherwise to do, perform, exercise or execute or concur with any other person or persons in doing, performing or exercising in or for any country or countries or jurisdiction in any part of the world all or any of the following powers, acts, deeds and things in connection with: letters patent, including extensions thereto; utility models; copyrights; trademark registrations; trademarks; trade names; trade dress; logos; design rights; designs and all rights analogous thereto and all applications therefor and any other forms whatsoever of intellectual property rights; including know-how, all of which are hereinafter called "Intellectual Property Rights", that is to say:

1. In any country or countries or jurisdiction in any part of the world to make application or cause application to be made for the grant or issue or transfer to the Company or registration in its name of Intellectual Property Rights and to take all steps necessary for the same to be prosecuted, maintained, withdrawn, renewed, enforced, defended or extended.
2. As the act and deed of the Company to sign, seal, deliver and execute all or any assignments or assurances, licences to the Company of or under any Intellectual Property Rights or the right to and interest in any inventions to be the subject of Intellectual Property Rights for the purpose of fully and effectually vesting and transferring the same in and to the Company.
3. As the act and deed of the Company to sign and execute all or any assignments and acceptances of the transfer or assignment of such rights, and also any licences, sub-licences and consents from the Company of or under any Intellectual Property Rights or the right to and interest in any invention to be the subject of Intellectual Property Rights, for the purpose of fully and effectually vesting transferring or granting the same in and to any entity, whether in the United Kingdom or elsewhere, in so far as such documents can be executed without the Company's seal being affixed thereto. For purposes of this Power of Attorney, the terms "entity" means, and includes, any person, firm or company or group of persons or unincorporated body.
4. To give undertakings or assurances to third parties and to any Trademark Registry or official intellectual property agency or governmental department or otherwise responsible for the registration or protection of trademarks, trade names, trade dress, logos, design rights or designs for the purpose of best protecting or ensuring the co-existence of the Company's rights to trademarks, trade names, trade dress, logos, design rights or designs.
5. To commence, prosecute and defend any proceedings or applications whether judicial or extra judicial relating to Intellectual Property Rights and to maintain, withdraw or settle the same.
6. For and in connection with any Intellectual Property Rights to sign, seal, deliver and execute any Power of Attorney or other deed or document authorising any agent,

- 2 -

- including trademark and patent agents and attorneys, to act on behalf of the Company.
7. To apply for the registration, amendment or cancellation of user rights in respect of any trademark or trade name.
 8. To act in regard to all official communications which may now or hereafter be addressed to the Attorneys relating to Intellectual Property Rights or the renewal thereof in such manner that the Attorneys may be recognised as the authorised agent(s) of the Company in all proceedings in relation thereto.
 9. For all or any of the purposes contained herein as the act and deed of the Company to sign, seal, deliver, execute and do all such documents, deeds, agreements, instruments and to do such acts as shall be requisite or may be deemed proper for or in relation to the said purposes.


AND THE COMPANY HEREBY RATIFIES and confirms and agrees to ratify and confirm all and whatsoever the Attorneys or any person, persons, firm or company appointed by them shall lawfully do or have done by virtue of the authorities herein contained

AND THE COMPANY HEREBY DECLARES that all instruments executed under and by virtue of this Power shall be as valid and effectual as if sealed by the Common Seal of the Company.

IN WITNESS whereof **GLAXO GROUP LIMITED** has caused its Common Seal to be hereunto affixed the day and year first before written


The **COMMON SEAL** of)
GLAXO GROUP LIMITED)
was hereto affixed in the presence of:)

Director



DIRECTOR

Secretary / Assistant Secretary



ASSIGNMENT

WHEREAS I/WE, Paul A HAMBLIN of Stevenage, Hertfordshire, GB (hereinafter called "the inventor(s)") have invented or discovered **"IMMUNOGENIC COMPOSITIONS COMPRISING A XENOGENIC PROSTATE PROTEIN P501S"** (hereinafter called "the invention") for which a patent application no. 0213364.3 was filed on **11 June 2002** and patent application no. 0221689.3 was filed on **18 September 2002** in the United Kingdom and for which an international patent application is now being filed designating the United States of America. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

(PCT/EP2003/006095 filed **6 June 2003**)

WHEREAS the invention, being made in the course of my employment, belongs to my/our employer, namely **GLAXOSMITHKLINE SERVICES UNLIMITED** a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, and

WHEREAS **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED**, a company incorporated in England and Wales whose registered address is 980 Great West Road, Brentford, Middlesex TW8 9GS, England, is desirous of acquiring from **GLAXOSMITHKLINE SERVICES UNLIMITED** the whole right, title and interest in and to the invention and the application, and

GLAXOSMITHKLINE SERVICES UNLIMITED and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** have authorised and requested my/our making the application, and

WHEREAS **GLAXO GROUP LIMITED** a company organised and existing under and by virtue of the laws of England and Wales and having its principal place of business at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England, is desirous of acquiring from **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** the whole right, title and interest in

and to the invention and the application in respect of the United States of America;

NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by **GLAXOSMITHKLINE SERVICES UNLIMITED** of the invention and the application by operation of law and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to **GLAXOSMITHKLINE SERVICES UNLIMITED**. **GLAXOSMITHKLINE SERVICES UNLIMITED** in turn hereby assigns and transfers to **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** its whole right, title and interest in and to the invention and the application. **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** in turn hereby assigns and transfers to **GLAXO GROUP LIMITED** its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** hereby authorise and request any patent arising therefrom in the United States of America be issued to **GLAXO GROUP LIMITED**.

AND **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **GLAXO GROUP**

LIMITED, its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.

IN WITNESS whereof and with effect from **11 June 2002** the inventor(s) and **Peter John GIDDINGS** as Attorney of both **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** by virtue of Powers of Attorney granted by **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED** respectively have hereunto set their respective hands.

SIGNED by Paul A HAMBLIN:

Date: 14/12/2004

SIGNED by Peter John GIDDINGS as the Attorney of each of **GLAXOSMITHKLINE SERVICES UNLIMITED** and **GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED**:

Bluddy

23 DEC 2004
Date: _____